Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT06633068
Recruiting Phase 2

The Analgesic Efficacy of Perineural Nalbuphine as an Adjuvant to Bupivacaine in Ultrasound Guided Superficial Cervical Plexus Nerve Block for Thyroid Surgeries. A Double Blinded Randomized Controlled Trial.

NCT06633068 · tracked via the Priya Life Science Egypt tracker
Sponsor
Cairo University
Phase
Phase 2
Started
2024-07-15
Last updated
2024-10-09

Condition(s) studied

Intra and Postoperative Pain Management

Investigational drug(s) / intervention(s)

Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block

Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block: Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries

Study summary

This study aiming to evaluate the analgesic effect of adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries regarding first rescue analgesia in the first twenty-four hours postoperative, VAS score after extubation and complications such as postoperative nausea, vomiting and respiratory depression.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients aged between 18 to 60 years old of both sexes undergoing elective thyroid surgery. * ASA I and II. Exclusion Criteria: * Patient refusal. * Hypersensitivity or contraindication to nalbuphine or bupivacaine. * Pregnancy or lactating mothers. * Hepatic, cardiac or renal diseases. * Bleeding disorders. * Severe neurological or psychological disorders. * Goitres with retrosternal extension. * Any anatomical disruption in the neck (ex: metastatic lymph nodes).

Primary outcome measure(s)

  • time to first rescue analgesia (will be given to VAS score > 4) following surgery in the first 24 hours. — First 24 hours postoperative
    defined as the time interval between the end of surgery and the first request to postoperative Nalbuphine

Trial sites (1)

FacilityCityRegionStatus
Kasr Alainy Teaching Hospitals Giza الجيزة Recruiting

More Cairo University trials in Egypt

The Link Between Periodontitis, Smoking and Oral Cancer Starting soon
Treating Intrabony Defect With MINST VS MINST Extended PRF Recruiting
Respiratory Exercises Versus Deep Neck Flexor Training in Chronic Mechanical Neck Pain Recruiting
Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure Starting soon
Preparation Time Of Bioflx Crowns Compared To Zirconia Crowns On Primary Molars Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06633068 on ClinicalTrials.gov ↗ ← All trials in Egypt